
ApoB Testing Could Sharpen Cholesterol Therapy Decisions
A Northwestern Medicine study in JAMA finds that apoB testing, which counts harmful cholesterol particles, better guides the decision to intensify cholesterol-lowering therapy than LDL or non-HDL testing, potentially preventing more heart attacks and strokes while remaining cost-effective for U.S. healthcare, based on a computer model comparing three strategies in 250,000 adults.





